Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (2292)	10/13/1997 1:43:00 PM
From: JOHN W.	of 6136

Press release from VRTX. biz.yahoo.com 1. After 12 weeks, only 70% reached undetectable levels (400 copies). 2. Well tolerated with diarrhea, nausea, headaches, and rash being the the most noticeable side effects. Viracept beats this drug hands down in every category: potency, side-effects, durability, convenience/compliance, and possibly cost. VX-478 is not a competitor to Viracept. It is not even a threat to Crixivan even if it gets to mkt in the next 2 yrs. Study the press release yourself!!!!!! I have 75 (Elise), 84 (Jay), do I hear 90? Doug?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next